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Abstract
Background: Recently, a number of studies conducted and published in China have suggested that traditional
Chinese medicine compound recipe (TCMCR) may be beneficial in the treatment of experimental traumatic brain
injury (TBI). In this study, we conducted a systematic review and meta-analysis of the efficacy of TCMCR in TBI
model with weight drop method to provide robust evidence on the effects of TCMCR and to determine whether
TCMCR can be recommended for routine treatment or considered as a standard treatment for TBI.
Methods: We identified eligible studies by searching five electronic databases on April 1, 2014, and pooled the
data using the random-effects model. Results were reported in terms of standardized mean difference (SMD). We
also calculated statistical heterogeneity, evaluated the studies’ methodological quality and investigated the
presence of publication bias.
Results: Totally, 187 relevant publications were searched from databases, 25 of which met our inclusion criteria. The
overall methodological quality of the most studies was poor, and there was evidence of statistical heterogeneity
among studies along with small-study effects. Meta-analysis showed statistically significant effects indicating that
TCMCR has a beneficial effect on TBI.
Conclusions: Despite the limitations, we concluded that TCMCR may reduce brain water content, improve BBB
permeability, and decrease TNF-α/NO expression after experimental TBI in terms of overall efficacy. However, our
review also indicates that more well-designed and well-reported animal studies are needed.
Keywords: Meta-analysis, Systematic review, Traumatic brain injury, Traditional Chinese medicine compound recipe
Background
Traumatic brain injury (TBI) remains the leading cause
of long-term disability in individuals under 35 years
worldwide [1], severely affects the quality of life of sur-
viving patients and brings a significant social and eco-
nomic burden. However, there is currently no effective
pharmacological interventions options for TBI [2].
Because research aimed at therapy development has fo-
cused almost exclusively on single therapies, all of which
have failed in multicenter clinical trials [3]. Fortunately,
the focus of research has recently shifted to modify mul-
tiple targets, either through combination therapies or
through the use of single agents that modulate multiple
key secondary events following TBI [4, 5].
For thousands of years, traditional Chinese medicine
(TCM) has been widely practice in China, and holds a
key role in maintaining the health of the Chinese popu-
lation, merits far greater attention from researchers
because of its diverse pharmacological functions and
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targets, which can provide improved treatment of
complex diseases by its ability to aim at several targets
simultaneously [5]. The traditional Chinese medicine
compound recipe (TCMCR), the main form of TCM
drug treatment, may represent an ideal source for devel-
oping safe and effective agents for TBI treatment be-
cause it contains ≥2 Chinese herbs, and therefore more
closely conforms to TCM theories and more accurately
reflects the characteristics of TCM than does the admin-
istration of a single herb [6]. Recently, a number of stud-
ies conducted and published in China have suggested
that TCMCR may be beneficial in TBI treatment and re-
habilitation [7–11]. However, it is uncertain whether ro-
bust evidence exists on the effects of TCMCR or
whether TCMCR can be recommended either for rou-
tine treatment or considered as a standard treatment for
TBI. Moreover, a systematic review and meta-analysis of
the efficacy of TCMCR in treating TBI has not yet been
investigated in experimental animal studies.
Therefore, the primary aim of the present study was to
conduct a systematic review and meta-analysis to inves-
tigate in an unbias manner whether the evidence from
experimental studies indicated a beneficial effect of
TCMCR in the treatment of TBI in animal models.
Methods
Literature search
All studies reporting the efficacy of TCMCR in animal
TBI models prior to April 1, 2014 were included. Arti-
cles were searched in the following databases: PubMed,
ScienceDirect, CNKI, Wan-Fang Data, and Vip. The key
search terms are summarized in Table 1 and were kept
broad to capture all potentially relevant articles. In
addition, the reference lists of all relevant articles were
searched for further relevant publications.
Study selection
Three investigators assessed the records to assess for eli-
gibility based on title, abstracts. The copies of all
relevant articles were obtained and further assessed
whether each met the prespecified inclusion criteria, the
details of which are presented in Table 2. Disagreements
among investigators were resolved by consensus after
discussion.
Data extraction
Two investigators independently extracted details of
each included studies including the animal species used,
type of TBI model, treatment groups, time/dose of drug
administration, anesthetic used, and the main outcomes.
Information on sample sizes and substances used as ex-
perimental and control treatments was also extracted.
Disagreements were resolved through consultation with
a third party author.
When sufficient data were not available, authors were
contacted and requested to provide missing data. The
digital ruler software was used to estimate numerical
values from the graphs, if no reply was received. And
the study was excluded from the meta-analysis, when
the required data were not obtainable.
Study quality
The methodological quality of each included studies was
assessed based on a 10-point quality checklist modified
from the CAMARADES study as previously described,
with minor modifications [12, 13], comprising (1) publi-
cation in a peer-reviewed journal; (2) random group al-
location; (3) blinded induction of brain injury; (4)
blinded assessment of outcome; (5) monitoring of
physiological parameters including temperature; (6) sam-
ple size calculation; (7) compliance with animal welfare
regulations; (8) avoidance of anesthetics with marked in-
trinsic neuroprotective properties (ketamine); (9) state-
ment of potential conflicts of interest; (10) use of
accurate/suitable/adequate animal models.
One point was given for written evidence of the qual-
ity criteria.
Statistical analysis
Data were processed as described previously [14]. Briefly,
for the meta-analysis, results were calculated as stan-
dardized mean difference (SMD), and 95 % confidence
intervals (CI) with random-effects model to avoid het-
erogeneity were used to assay differences of the global
estimate effect [13]. The Cochran’s Q-statistic was used
to assess within- and between-study variation or hetero-
geneity [15, 16]. Heterogeneity was quantified with the
I2 metric, with higher values denoting a greater degree
of heterogeneity. I2 values ≤ 50 % indicate acceptable
heterogeneity among studies [17]. For studies comparing
different doses and/or timing of drug administration
with a single control group, we pooled data from all ex-
perimental groups for comparison with the control
Table 1 Key search terms used in database searches
Traumatic brain injury traditional Chinese medicine compound recipe
Traumatic brain injury traditional Chinese medicine compound recipe
Traumatic brain injuries traditional Chinese medicine recipe
Head injury traditional Chinese herb medicine
Head injuries traditional Chinese medicine
Brain injury Chinese herb medicine
Brain injuries Chinese medicine
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group. The possible publication bias was assessed using
funnel plots and Egger’s tests. [18]. All statistical ana-
lyses were performed using Stata software (version 12.0).
Results
Study selection
On the basis of predefined standards, we identified 187
potentially relevant articles. After removing duplicate
articles, 95 articles remained. Through screening titles
and abstracts, 68 were excluded because they were not
published in peer-reviewed journals, TCMCR was not
administered orally, or traditional Chinese medicine in-
jection/a single Chinese herb medicine was adminis-
tered in the treatment group. After full-text evaluation
of the remaining 26 articles, one article was excluded
due to unobtainable data. Thus, 25 studies [7, 8, 19–41]
were included for systematic review. Moreover, 14 stud-
ies [8, 19, 22–29, 32, 34, 35, 38] were ultimately in-
cluded in the meta-analysis. Figure 1 shows a flow
chart of the study selection.
Table 2 Criteria for the inclusion/exclusion of studies
Inclusion criteria Exclusion criteria
1. Published in peer-viewed journal 1. Non-published studies and dissertations
2. Was published in English or Chinese 2. No control group
3. TCMCR was administered orally 3. TCMCR administered in other methods (e.g. Intraperitoneally,
subcutaneously, etc.)
4. Experimental TBI was induced in rodents 5. Examined other types of animals (e.g. sheep, cat, dog etc.)
5. Had a TBI treatment group that was treated with TCMCR and TBI
control group that was administered a placebo following injury
6. Administration of traditional Chinese injection or a single
Chinese herb in the treatment group
6. Investigators employed weight-drop methods to induce brain trauma 7. Involved non-impact (e.g. cortical ablation) or penetrating TBI.
(e.g. missile-induced TBI)
8. Duplicate publications
Fig. 1 PRISMA flowchart of the study selection
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Study characteristics
The 25 included studies were all conducted in China
and published between 2001 and 2014. Of these, two
studies [8, 41] were published in English and 23 others
in Chinese. Four studies [22, 30, 34, 39] examined effects
in Wistar rats, two [27, 29] in Kunming mice, and 19 in
SD rats. The drugs administered to the treatment groups
included Naozhenning granules [27], Naochuangning
[27, 39], Brain injury compound decoction [37], Tongfu-
jiannao oral liquid [23], Naoshuning [24–26, 32, 35, 38],
Shenqi extraction [29], compound Huangjinxiang extrac-
tion liquid [40], Quyu Tongfu decoction [40], Angong
Niuhuang pill [21, 28], Sanhuang Xiexin decoction [22],
Brain Compound decoction [30, 34], Huayu capsules
[41], modified “Shengyu” decoction [7, 8], Longxuejie
capsules [19], and Jiannao Yizhi capsules [20, 31, 33, 36].
For outcome measurements, brain water content was
calculated in 12 studies [8, 22–29, 32, 38], blood–
brain barrier permeability was measured in seven
studies [24, 25, 27–29, 35, 38], cognitive impairment
was evaluated in two trials [37, 39], the TNF-α level
was detected in three studies [8, 19, 29] and the NO
level was detected in two studies [19, 34]. The char-
acteristics of these studies are listed in Table 3.
Methodological quality of included studies
Overall, the median quality of the 25 included studies
was poor (3, interquartile range, 3–4) with scores ran-
ging from 2 to 6. No studies scored 0 or had a high
quality rating (7–10 points). We found one study [8]
with a quality score of 6, three [30, 34, 40] with a score
of 5, and four [21, 29, 37, 39] with a score of 4. Animals
were allocated treatment by randomization in all in-
cluded articles except one [27]. Only two studies [8, 40]
that were included failed to report the monitoring of
physiological parameters (although the majority of these
only monitored body temperature). All of the studies
failed to report potential conflicts of interest, blinded
outcome assessment, and blinded induction of TBI.
Meta-analysis
Brain water content
In 12 studies [8, 22–29, 32, 38], there were 25 compari-
sons (involving 432 animals) of brain water content after
TBI, which was determined by the wet and dry weight
method [42]. Pooled analysis indicated that animals in the
treatment groups had significantly reduced brain water
content compared to animals in the control groups
(SMD = -1.421, 95 % CI: -1.704 to -1.1379, P < 0.0001).
There was evidence of little heterogeneity among stud-
ies (χ2 = 39.51, df = 24 (P = 0.024), I2 = 39.2 %), and
small-study effects (Egger’s test bias coefficient = -5.8081,
95 % CI: -7.7275 to -3.8888, P < 0.001). (Figs. 2a and 3)
Integrity of blood–brain barrier
In seven included trials [24, 25, 27–29, 35, 38], there
were 12 comparisons (involving 224 animals) of blood–
brain-barrier integrity after TBI, which was analyzed by
assessing extravasation of Evans blue dye [43]. The
pooled analysis indicated that animals in the treatment
groups had significantly better blood–brain barrier in-
tegrity than animals in the control groups (SMD =
−1.481; 95 % CI: −1.815 to −1.146; P < 0.0001).
There was evidence of little heterogeneity among
studies (χ2 = 13.19, df = 11 (P = 0.281), I2 = 16.6 %),
and small-study effects (Egger’s test bias coefficient =
−8.2850, 95 % CI: −10.3545 to −6.21546, P < 0.001).
(Figs. 2b and 4)
TNF-α levels
In three studies [8, 19, 29], there were seven compari-
sons (involving 120 animals) of TNF-αafter TBI. The
pooled analysis indicated that there was a significant dif-
ference in TNF-αlevels between the treatment and con-
trol groups (SMD = −1.291; 95 % CI, −1.809 to −0.774;
P < 0.0001).
There was evidence of little heterogeneity among stud-
ies (χ2 = 9.39, df = 6 (P = 0.153), I2 = 36.1 %). Publication
bias could not be assessed because of the small number
of studies (<10 studies) [44, 45]. (Fig. 5a)
NO levels
In two studies [19, 34], there were six comparisons (in-
volving 108 animals) of NO after TBI. The pooled ana-
lysis indicated that there was a significant difference in
NO levels between the treatment and control groups
(SMD = −1.550; 95 % CI, −1.987 to −1.112; P < 0.0001).
There was no evidence of heterogeneity among studies
(χ2 = 1.34, df = 5 (P = 0.931), I2 = 0 %). Publication bias
could not be assessed because of the small number of
studies (<10 studies) [44, 45]. (Fig. 5b)
Possible drug protection mechanism analysis
All of the studies selected during initial screening
assessed the biological mechanisms of TCMCR activity.
A wide variety of possible neuroprotective mechanisms
were proposed in these studies. The neuroprotective ef-
fect of TCMCR was attributed primarily to preservation
of blood–brain barrier integrity, amelioration of cerebral
edema, and inhibition of inflammatory response. In
addition, it was found that TCMCR may regulate cere-
bral blood flow. (Table 4)
Discussion
To date, numerous clinical trials [46–48] that have
sought new therapeutic agents for treating TBI have
proven unsuccessful. However, there is increasing evi-
dence that traditional Chinese medicine, including
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Table 3 Characteristics of included studies
Study Animal Species Treatment Groups(Drug/Dose) Anaesthetic used Time of administration Main Outcomes Quality Score




Unknown 7 days before injury




Zhang 2002 [3] SD rats ①Brain injury compound decoction
(unknown)
Ether 3 days before injury













Zhang 2004 [5] SD rats ①Tongfujiannao Oral Liquid(7.5 g/kg)
②Tongfujiannao Oral Liquid(3.125 g/kg)
Unknown After injury
Daily for 3 days




Cui 2005a [6] Male SD rats ①Naoshuning(15 g/kg) chloralhydrate 3 days before injury




Cui 2005b [7] MaleSD rats ①Naoshuning(15 g/kg) chloralhydrate 3 days before injury
Twice for 4 days
BBB permeabilityBrain water content
MMP-9
3
Yu 2005 [8] Kunmingmice ①Shenqi Extraction (0.28 g/kg)
②Shenqi Extraction (0.14 g/kg)
③Shenqi Extraction (0.07 g/kg)
Ether 3 days before injury





Zhou 2007 [9] MixedSD rats ① Huayu capsule (1.030 g/kg)
② Huayu capsule (0.515 g/kg)
③ Huayu capsule (0.258 g/kg)
chloralhydrate After injury
Daily for 7 days
① Nerve-muscle catching capability.
② Histopathological
3
Cui 2008a [10] MaleSD rats ①Naoshuning(7.5 g/kg) chloralhydrate 3 days before injury




Cui 2008b [11] MaleSD rats ①Naoshuning(7.5 g/kg) Unknown 3 days before injury





Miao 2008 [12] MaleWistar rats ①Brain Compound decoction(10 g/kg) Pentobarbital Immediately after injury
Twice for 7 days
Na+-K+-ATPCa2+-ATP 5
Cui 2009a [13] SD rats ①Naoshuning(7.5 g/kg) Unknown 3 days before injury





Cui 2009b [14] MaleSD rats ①Naoshuning(7.5 g/kg) Unknown 3 days before injury





Xiong 2009 [15] SD rats ①Quyu Tongfu decoction(10 ml/kg)
②compound Huangjinxiang extraction
liquid(10 ml/kg)
Pentobarbital 20 min after injury
Daily for 24 h
AQP- 4 content 5
Xie 2010 [16] MixedSD rats ① Angong Niuhuang Pill(0.6 g/kg) chloralhydrate 12 h before injury






















Table 3 Characteristics of included studies (Continued)
Xu 2010 [17] Mixed
SD rats
①Angong Niuhuang Pill(0.121 g/2 ml) Pentobarbital After injury




Miao 2011 [18] Male
Wistar rats
①Brain Compound decoction(10 g/kg) Pentobarbital Immediately after injury





Zhang 2011 [19] Wistar rats ①Sanhuang Xiexin Decoction(10 g/kg) chloralhydrate Immediately after injury
Daily for 72 h
NF-κB\IL- 6 content 3
Wang 2012a [20] SD rats ①Longxuejie capsule (2.6 mg/g/d) Unknown after injury
Daily for 5d
NO\TNF-α content (serum) 3




Unknown 6 h after injury




Zhao 2012 [22] Mixed
SD rats
①JiannaoYizhi capsules(6.0 g/kg/d) chloral hydrate 24 h after injury
Daily for 10d
CGRP content (Plasma) 3
Zhou 2012 [23] SD rats ①JiannaoYizhi capsules(6.0 g/kg/d) chloral hydrate 24 h after injury
Daily for 10d
NPY content (serum) 3
Fan 2013a [24] SD rats ①JiannaoYizhi capsules(6.0 g/kg/d) chloral hydrate 24 h after injury
Daily for 10d
S100B content (serum) 3
Fan 2013b [25] SD rats ①JiannaoYizhi capsules(6.0 g/kg/d) chloral hydrate 24 h after injury
Daily for 10d
NSE content (serum) 3
Zhao 2014 [26] Male
SD rats
①modified “Shengyu”decoction 0.5 mL/200 g
②modified “Shengyu”decoction 1.0 mL/200 g
③modified “Shengyu”decoction 2.0 mL/200 g






TNF-α\ IL-1\IL-6\IL-10 content (brain)
6
Note: BBB Blood–brain-barrier, MMP-9 matrix metalloprotein 9, TNF-α tumor necrosis factor-α, IL-1 interleukin-1, IL-6 interleukin-6, IL-10 interleukin-10, NSE 2-phospho-D-glycerate hydrolase, NPY Neuropeptide Y, CGRP


















TCMCR, extracts, and acupuncture, have clinical benefit
in the treatment of TBI patients [49–51]. Because
TCMCR is the main form of TCM drug treatment, ro-
bust evidence of its effects on TBI must be provided.
Therefore, we have conducted the first systematic review
and meta-analysis of the effects of TCMCR in animal
models of TBI. Because systematic review and meta-
analysis of animal experiments could provide strong evi-
dence in an unbiased manner. Although small-study ef-
fects and statistical heterogeneity among studies were
present, our results indicated that TCMCR potentially
exerts neuroprotective effects in terms of reduction of
brain water content, amelioration of BBB permeability,
and deduction of TNF-α/NO after TBI. Similar work
[52] was performed in the context of experimental
stroke that demonstrated the neuroprotective effects of
Buyang Huanwu decoction, a well-known TCMCR, on
animal stroke models. Though they are different dis-
eases, many aspects of their respective pathologies are
similar, and these investigations provide further evidence
of the neuroprotective efficacy of TCMCR, supporting
its potential use for human TBI therapy.
Concerning study quality, we found that the methodo-
logical quality of most included studies was generally
poor, as many failed to report blinded outcome assess-
ment, blinded induction of TBI, sample size calculation,
compliance with animal welfare regulations, and poten-
tial conflicts of interest. However, because we sought to
report on overall quality, we did not arbitrarily exclude
them solely on the basis of these defects [53].
The current study has some limitations that have also
been observed in previous studies [18, 54, 55]. First,
Fig. 3 Begg’s funnel plot of brain water content. There was evidence of small study effects (Egger’s test bias coefficient = −5.8081, 95 % CI:
−7.7275 to −3.8888, P <0.001)
Fig. 2 Meta-analysis of effect of TCMCR on brain water content reduction (a) and integrity of BBB improvement (b). The horizontal lines represent the
mean estimated effect size and the 95 % confidence intervals(CI) for each individual comparison according to their effect on brain water content
(a) and integrity of BBB (b). The SMD and the 95 % CI of the global estimate are represented as solid and dashed vertical lines, respectively
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although we made an effort to identify all relevant stud-
ies, our analysis could only be based on articles pub-
lished in English or Chinese and did not take the
unpublished data and the relevant articles published in
other languages into account. Moreover, most of them
published in local journal particularly, some publications
were showed in journal from university. So there was
evidence of small-study effects and publication bias
should be considered. Second, no studies specifying the
degree of severity (e.g., mild, moderate, or severe). The
results of different studies could have been more accur-
ately compared if injury severity had been reported con-
sistently. Third, as in previous studies [56–58], the
methodological quality of the included studies was gen-
erally poor. Due to the poor quality of the studies, the
results of this review are likely to be influenced by many
factors. Of course, it should be noted that negative judg-
ment did not necessarily indicate that the experiment it-
self was performed inadequately; it indicated that there
was inadequate information for assessing its quality.
Fourth, although the findings indicate that TCMCR
treatment benefits can be found in the TBI model with
weight-drop mothed. For the weight-drop model, this
model is limited in the production of primary lesions
that are macroscopically meaningful once it is not cap-
able of creating cranial fractures with levels of energy
compatible with life after impact. It presented discrete
focal lesions in a small number of animals and only at
elevated levels of energy, but in accordance with what
was described in similar studies [59]. Moreover, any sin-
gle animal model may not be able to fully mimic the
highly heterogeneous nature of human TBI [60]. Lastly,
Fig. 5 Meta-analysis of effect of TCMCR on the reduction of TNF-α(a) and NO(b). The horizontal lines represent the mean estimated effect size
and the 95 % confidence intervals(CI) for each individual comparison according to their effect on TNF-α(a) and NO (b). The SMD and the 95 % CI
of the global estimate are represented as solid and dashed vertical lines, respectively
Fig. 4 Begg’s funnel plot of integrity of BBB. There was evidence of small study effects (Egger’s test bias coefficient = −8.2850, 95 % CI: −10.3545
to −6.21546, P <0.001)
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we limited our analysis to the alternation of BBB integ-
rity, brain water content, and TNF-α/NO levels follow-
ing TBI, largely due to insufficient data regarding
histopathology, such as lesion volume and neurobehav-
ioral outcomes such as cognitive performance and motor
function.
Additionally, heterogeneity must be considered for any
meta-analysis. The main reasons for heterogeneity were
the limited number of trials and small cohorts [61];
therefore, additional large-scale clinical trials are re-
quired. Another important reason for the existence of
heterogeneity was the low quality and potential bias of
the trials selected for analysis. The surprisingly low het-
erogeneity of NO levels in the meta-analysis requires
further consideration. It is also associated with the poor
methodological quality of the selected trials, which re-
quire additional investigation.
To improve the clinical translation, our recommenda-
tions for the conduct of future animal studies of TCMCR
or other TCM drugs are as follows: (1) More studies have
shown that TCMCR is a whole greater than the sum of its
parts in terms of its composition and pharmacodynamic
action. In order to make full use of the advantages offered
by TCMCR, it is essential to address the difficulties in
studying TCMCR, including the role played by the mater-
ial basis and physical basis in TCM’s therapeutic effects,
and the rules of compatibility, pharmacology, and action
mechanism of TCMCR [62]; (2) Other TBI models are
needed to investigate the effects of TCM/TCMCR on TBI;
(3) Further researchers are strongly recommended to con-
sult and follow the ARRIVE (Animal Research: Reporting
In Vivo Experiments) guidelines to report their animal ex-
perimental results [63, 64]; (4) Other long-term neuro-
psychological outcomes should also be focused on, such
as the cognitive performance, the motor function.
Conclusions
Despite limitations, the animal data has shown that
TCMCR may be neuroprotective in the TBI model with
weight-drop mothed. However, successful clinical transla-
tion of this neuroprotective strategy necessitates rigorous,
robust, and detailed pre-clinical evaluation. Therefore,
additional well-designed and well-reported experimental
animal studies are needed.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
W.P. and B. Y. conceived of the study, and participated in its design and
coordination and drafted the manuscript; Z.W., Y.W., and C. S. carried out the
literature search, study selection and helped to draft the manuscript; J.Z. and
X. X. participated in the data extraction, performed the statistical analysis,
and helped to draft the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
This work was financially supported by the National Natural Science
Foundation of China (NO. 81303074).
Author details
1Institute of Integrated Medicine, Xiangya Hospital, Central South University,
Changsha 410008, China. 2Department of Integrated Chinese and Western
Medicine, The Second Xiangya Hospital, Central South University, No.139
Middle Renmin Road, Changsha, Hunan 410011, P.R. China.
Received: 3 September 2015 Accepted: 3 March 2016
References
1. Feigin VL, Theadom A, Barker-Collo S, Starkey NJ, McPherson K, Kahan M,
Dowell A, Brown P, Parag V, Kydd R, et al. Incidence of traumatic brain
injury in New Zealand: a population-based study. Lancet Neurol. 2013;12(1):
53–64.
2. Janowitz T, Menon DK. Exploring new routes for neuroprotective drug
development in traumatic brain injury. Sci Transl Med. 2010;2(27):27rv21.
3. Margulies S, Hicks R, Combination Therapies for Traumatic Brain Injury
Workshop L. Combination therapies for traumatic brain injury: prospective
considerations. J Neurotrauma. 2009;26(6):925–39.
4. Kabadi SV, Faden AI. Neuroprotective strategies for traumatic brain injury:
improving clinical translation. Int J Mol Sci. 2014;15(1):1216–36.
5. Frantz S. Drug discovery: playing dirty. Nature. 2005;437(7061):942–3.
6. Zhong YQ, Fu JJ, Liu XM, Diao X, Mao B, Fan T, Yang HM, Liu GJ, Zhang WB.
The reporting quality, scientific rigor, and ethics of randomized placebo-
controlled trials of traditional Chinese medicine compound formulations
and the differences between Chinese and non-Chinese trials. Curr Ther Res
Clin Exp. 2010;71(1):30–49.
7. Wang Y, Li Y, Xi X, Ma D. Effect of modified”Shengyu” decoction on the
apoptosis of neural cells after traumatic brain injury in rats. Med J Commun.
2012;26(4):312–5.
8. Zhao GW, Wang Y, Li YC, Jiang ZL, Sun L, Xi X, He P, Wang GH, Xu SH, Ma
DM, et al. The neuroprotective effect of modified “Shengyu” decoction is
mediated through an anti-inflammatory mechanism in the rat after
traumatic brain injury. J Ethnopharmacol. 2014;151(1):694–703.
9. Sun M, Zhang JJ, Shan JZ, Zhang H, Jin CY, Xu S, Wang YL. Clinical
observation of Danhong Injection (herbal TCM product from Radix Salviae
miltiorrhizae and Flos Carthami tinctorii) in the treatment of traumatic
intracranial hematoma. Phytomedicine. 2009;16(8):683–9.
10. Jin X, Shen G, Gao F, Zheng X, Xu X, Shen F, Li G, Gong J, Wen L, Yang X,
et al. Traditional Chinese drug ShuXueTong facilitates angiogenesis during
wound healing following traumatic brain injury. J Ethnopharmacol. 2008;
117(3):473–7.
11. Bai Y, Yao HX, Hu ML, Wang LR, Jin LD, Wang WT, Lin LN. Effects of shenmai
injection on pulmonary aquaporin 1 in rats following traumatic brain injury.
Chin Med J (Engl). 2011;124(3):457–60.
Table 4 Possible protective mechanisms of TCMCR
Possible drug protective mechanisms Studies
Increase in cerebral microvascular
patency and integrity
[11]
Improve cognitive deficits [3, 4]
Ameliorated cerebral edema [1, 5–8, 10, 13–16, 19, 26]
Attenuated disruption of the
blood–brain-barrier
[1, 7, 8, 10, 11, 14, 16, 24, 25]
Reduced the neuronal apoptosis [9, 21]
Suppressed oxidative stress [5, 18, 20]
Regulation of cerebral blood flow [4, 8, 22, 23]
Increase activities of Na+-K+-ATPase、
Ca2+-ATPase and regulation of Ca2+
[12]
promote the synthesizing and secreting
of apolipoprotein E
[17]
Inhibited the inflammatory response [5, 8, 19, 20, 26]
Yang et al. BMC Complementary and Alternative Medicine  (2016) 16:95 Page 9 of 11
12. Macleod MR, O’Collins T, Howells DW, Donnan GA. Pooling of animal
experimental data reveals influence of study design and publication bias.
Stroke. 2004;35(5):1203–8.
13. Garcia-Bonilla L, Campos M, Giralt D, Salat D, Chacon P, Hernandez-
Guillamon M, Rosell A, Montaner J. Evidence for the efficacy of statins in
animal stroke models: a meta-analysis. J Neurochem. 2012;122(2):233–43.
14. Peng W, Xing Z, Yang J, Wang Y, Wang W, Huang W. The efficacy of
erythropoietin in treating experimental traumatic brain injury: a systematic
review of controlled trials in animal models. J Neurosurg. 2014;121(3):653–64.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
16. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses
of randomized controlled trials. N Engl J Med. 1987;316(8):450–5.
17. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of
Interventions version 5.1.0 (updated March 2011). Cochrane Collaboration.
2011 [Epub ahead of print].
18. Ker K, Perel P, Blackhall K. Beta-2 receptor antagonists for traumatic brain
injury: a systematic review of controlled trials in animal models. CNS
Neurosci Ther. 2009;15(1):52–64.
19. Wang M, Li J. Effects of Longxuejie capsule on nitric oxide and tumor necrosis
factor-α in serum of rats with craniocerebral injury. Modern J Integrated
Traditional Chinese and Western Medicine. 2012;21(12):1279–80.
20. Zhou Z, Fan X, Zhao X, Hou W, Zhang Y, Bai L, Fang Y. Effect of Jiannao
Yizhi capsules on blood neuropeptide Y in model rats with traumatic brain
injury. Modern J Integrated Chinese Traditional and Western Medicine. 2012;
21(31):3437–9.
21. Xu Z, Huang L, Dai Y, Wang Y. Effects of Angongniuhuang Pill on the
Synthesis of ApolipoproteinE in Brains of Rats after Traumatic Brain Injury.
J Zhejiang University of Traditional Chinese Medicine. 2010;34(4):487–8.
22. Zhang G, Ling J, Yan M, Wang D. Effect of Sanhuang Xiexin Decoction on
Expression of Cerebral Nuclear -κB and Interleukin-6 in Rats after Severe
Traumatic Brain Injury. J New Chinese Medicine. 2011;43(5):135–7.
23. Zhang Q, Wang Y, Cheng H, Zhang C, Wang J. Experimental Study on Effect
of Tongfujiannao Oral Liquid for Rats with Craniocerebral Trauma.
J Emergency in Traditional Chinese Medicine. 2004;13(5):309–10.
24. Cui X, Yin L, Wang Y-l. Effects of Naoshuning on permeability of blood-brain
barrier and MMP-9 expression in TBI rats. J Beijing University of Traditional
Chinese Medicine. 2005;28(2):60–2.
25. Cui X, Yin L, Wang Y, Zhang X, Zhang M. Effects of Naoshuning on brain water
content and the protein expression of AQP4 in rats with traumatic brain injury.
J Beijing University of Traditional Chinese Medicine. 2008;31(7):474–7.
26. Cui X, Liu M, Zhao J, Wang Y-l, Zhao Y. Dynamic observation on
interventional effect of Naoshuning on traumatic brain edema in rats by
using MRI. J Beijing University of Traditional Chinese Medicine. 2009;32(11):
747–50.
27. Long Z, Wang T, Wang X, Xia K, Wang Z. Effect of Naochuangning on
cerebral edema and permeability of blood-brain barrier. J Anhui Traditional
Chinese Medical College. 2001;20(2):41–3.
28. Xie Y, Zhu W. Effects of Angongniuhuang Pill on cerebral edema and
permeability of blood-brain barrier in rats after traumatic brain injury.
International Medicine and Health Guidance News 2010, 16(17). [Epub
ahead of print]
29. Yu H, Wang Q, Zhou S. Effect of Shenqi extraction on closed craniocerebral
injury in mice. Chinese J Veterinary Drug. 2005;39(3):16–8.
30. Miao K, Wu X, Chen Q, Zhang X. Effect of compound decotion on activities
of Na + -K + -ATPase、Ca2 + -ATPase and regulation of Ca2+ after traumatic
brain injury. Chinese J Trauma. 2008;24(12):1002–6.
31. Fan X, Bai L, Zhao X, Zhang Y, Zhou Z-g, Chang T. Effect of Jiannao Yizhi
Capsules on Blood S100B in Modle Rats with Traumatic Brain Injury. Chinese
J Traditional Medical Science and Technology. 2013;20(1):23–4.
32. Cui X, Yin L, Wang Y. Effects of Naoshuning on neurological outcome
following traumatic brain injury in rats. Chinese J Rehabilitation Theory and
Practice. 2005;11(1):21–2.
33. Zhao X, Fan X, Hou W, Zhang Y, Zhou Z-g, Bai L-n, Fang Y. Effect of Jiannao
Yizhi capsules on plasma levels of calcitonin gene-related peptide in rats
with traumatic brain injury. Chinese J Integrated Traditional and Western
Medicine in Intensive and Critical Care. 2012;19(5):290–2.
34. Miao J, Chen Q, Wu X, Liu Z, Zhang X. Effects of compound decotion on
activity and expression of nitric oxide and neuronal nitric oxide synthase in
the brain of traumatic brain injury rat model. Chinese J Clinical
Pharmacology and Therapeutics. 2011;16(11):1340–6.
35. Cui X, Yin L, Wang Y, Zhang X, Zhang M, Chen H, Liu F. Experimental Study
on Protective Role of Naoshuning on Micro-Cerebral Blood Vessels in Brain-
Injured Rats. Chinese J Basic Medicine In Traditional Chinese Medicine. 2008;
14(3):188–190+240.
36. Fan X, Zhao X, Zhou Z-g, Zhang Y, Chang T, Bai L, Hou W, Fang Y, Zhou F.
Effect of Jiannao Yizhi Capsules on Blood NSE in Modle Rats with Traumatic
Brain Injury. Chinese Archives of Traditional Chinese Medicine. 2013;31(5):
1066–8.
37. Zhang J, Wang Z, Liu G, Lou J, Liu G, Zhu S. Brain injury compound decoction
ameliorates traumatic brain injury-induced cognitive impairment in rats. China
J Traditional Chinese Medicine and Pharmacy. 2002;17(4):251–2.
38. Cui X, Yin L, Wang Y, Zhang X, Zhang M, Zhao Y, Liu Z, Ju L. Effect of
Naoshuning on MMP-2/9 protein expression in traumatic brain injury rats.
China J Traditional Chinese Medicine and Pharmacy. 2009;24(2):211–3.
39. Wang T, Long Z, Bai M. Effect of Naochuangning on Memory and
Endothelin Content in Rats with Open Cerebral Laceration. China
J Experimental Traditional Medical Formulae. 2003;9(1):35–6.
40. Xiong G, Zhang D, Xiong L, Chai X, Bi C, Fan X. Effect of compound
Huangjinxiang extraction liquid on auuaporin 4 expression after experimental
traumatic brain injury in rats. Central South Pharmacy. 2009;7(3):165–7.
41. Zhou C, Zhang J, Wang Y, Qian H, Gong L, Huang G. Huayu capsule
enhances limb-catching capability of rats with experimental open traumatic
brain injury*. Neural Regeneration Research. 2007;2(4):221–4.
42. Bareyre F, Wahl F, McIntosh TK, Stutzmann JM. Time course of cerebral
edema after traumatic brain injury in rats: effects of riluzole and mannitol.
J Neurotrauma. 1997;14(11):839–49.
43. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and
matrix metalloproteinase-9 expression during reperfusion injury: mechanical
versus embolic focal ischemia in spontaneously hypertensive rats. Stroke.
2002;33(11):2711–7.
44. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-
analysis: power of statistical tests and prevalence in the literature. J Clin
Epidemiol. 2000;53(11):1119–29.
45. Singh B, Parsaik AK, Prokop LJ, Mittal MK. Endovascular therapy for acute
ischemic stroke: a systematic review and meta-analysis. Mayo Clinic
Proceedings Mayo Clinic. 2013;88(10):1056–65.
46. Skolnick BE, Maas AI, Narayan RK, van der Hoop RG, MacAllister T, Ward JD,
Nelson NR, Stocchetti N, Investigators ST. A clinical trial of progesterone for
severe traumatic brain injury. N Engl J Med. 2014;371(26):2467–76.
47. Robertson CS, Hannay HJ, Yamal JM, Gopinath S, Goodman JC, Tilley BC,
Epo Severe TBITI, Baldwin A, Rivera Lara L, Saucedo-Crespo H, et al. Effect of
erythropoietin and transfusion threshold on neurological recovery after
traumatic brain injury: a randomized clinical trial. JAMA. 2014;312(1):36–47.
48. Ripley DL, Morey CE, Gerber D, Harrison-Felix C, Brenner LA, Pretz CR, Cusick C,
Wesnes K. Atomoxetine for attention deficits following traumatic brain injury:
results from a randomized controlled trial. Brain Inj. 2014;28(12):1514–22.
49. Zhao W, Wang C, Li Z, Chen L, Li J, Cui W, Ding S, Xi Q, Wang F, Jia F, et al.
Efficacy and safety of transcutaneous electrical acupoint stimulation to treat
muscle spasticity following brain injury: a double-blinded, multicenter,
randomized controlled trial. PLoS One. 2015;10(2):e0116976.
50. Saito S, Kobayashi T, Osawa T, Kato S. Effectiveness of Japanese herbal
medicine yokukansan for alleviating psychiatric symptoms after traumatic
brain injury. Psychogeriatrics. 2010;10(1):45–8.
51. Gu J, Zhang X, Fei Z, Wen A, Qin S, Yi S, Chen Y, Li X. [Rhubarb extracts in
treating complications of severe cerebral injury]. Chin Med J (Engl). 2000;
113(6):529–31.
52. Wei RL, Teng HJ, Yin B, Xu Y, Du Y, He FP, Chu KT, Luo BY, Zheng GQ. A
systematic review and meta-analysis of buyang huanwu decoction in
animal model of focal cerebral ischemia. Evid Based Complement Alternat
Med. 2013;2013:138484.
53. Wardlaw JM, Warlow CP, Sandercock PA, Dennis MS, Lindley RI.
Neuroprotection disappointment yet aGAIN. Lancet. 2000;356(9229):597.
54. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M,
Mignini LE, Jayaram P, Khan KS. Comparison of treatment effects between
animal experiments and clinical trials: systematic review. BMJ. 2007;
334(7586):197.
55. Wheaton P, Mathias JL, Vink R. Impact of pharmacological treatments on
outcome in adult rodents after traumatic brain injury: a meta-analysis.
J Psychopharmacol. 2011;25(12):1581–99.
56. Junhua Z, Menniti-Ippolito F, Xiumei G, Firenzuoli F, Boli Z, Massari M,
Hongcai S, Yuhong H, Ferrelli R, Limin H, et al. Complex traditional Chinese
Yang et al. BMC Complementary and Alternative Medicine  (2016) 16:95 Page 10 of 11
medicine for poststroke motor dysfunction: a systematic review. Stroke.
2009;40(8):2797–804.
57. Sheng C, Peng W, Xia Z-a, Wang Y, Chen Z, Su N, Wang Z. The impact of
ginsenosides on cognitive deficits in experimental animal studies of
Alzheimer’s disease: a systematic review. BMC Complement Altern Med
2015, 15(1). [Epub ahead of print]
58. Tao W, Luo X, Cui B, Liang D, Wang C, Duan Y, Li X, Zhou S, Zhao M, Li Y,
et al. Practice of traditional chinese medicine for psycho-behavioral
intervention improves quality of life in cancer patients: A systematic review
and meta-analysis. Oncotarget. 2015 [Epub ahead of print].
59. Silva Ddos S, Brito JN, Ibiapina JO, Lima MF, Medeiros AR, Queiroz BH,
Guedes VO. Traumatic brain injury: clinical and pathological parameters in
an experimental weightdrop model. Acta Cir Bras. 2011;26(2):94–100.
60. Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury.
Nat Rev Neurosci. 2013;14(2):128–42.
61. Peng W, Yang J, Yang B, Wang L, Xiong XG, Liang Q. Impact of statins on
cognitive deficits in adult male rodents after traumatic brain injury: a
systematic review. Biomed Res Int. 2014;2014:261409.
62. Sheng-shan D, Run-hui L, Peng J, Lei L, Chuan Z, Guo-an L, Wei-dong Z.
System biology and its application in compound recipe of traditional
Chinese medicine study. World Science and Technology. 2008;10(2):116–21.
63. Danos O, Davies K, Lehn P, Mulligan R. The ARRIVE guidelines, a welcome
improvement to standards for reporting animal research. J Gene Med. 2010;
12(7):559–60.
64. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving
bioscience research reporting: the ARRIVE guidelines for reporting animal
research. PLoS Biol. 2010;8(6):e1000412.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Yang et al. BMC Complementary and Alternative Medicine  (2016) 16:95 Page 11 of 11
